Alzamend Neuro Inc (ALZN) Noticias

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice

Alzamend is developing AL001, a lithium product designed for enhanced safety and efficacy compared to currently available FDA-approved and...

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Data confirm the positive topline results announced in June 2023 identifying a maximum tolerated dose as assessed by an independent safety...

Form 8-K - Current report

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the...

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference

Fireside conversation to take place on October 17, 2024, at 1:30 PM ET Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Alzamend Neuro Issues Letter to Stockholders

Alzamend recently announced partnership with Massachusetts General Hospital for five phase II clinical trials of AL001, involving healthy human...

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of...

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder 

Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of...

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder

Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of...

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease

Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of...

Form 8-K - Current report

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the...